Skip to main content
Equibles

SAMRATPH · SAMRAT PHARMACHEM LTD. · Financials

Use SAMRATPH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SAMRATPH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
260.40 INR +5.40 (+2.12%) At close · Nov 13
Rebalance outlook locked
Market Cap
804.56M INR
Shares
3.09M
Volume · Nov 13 682 Avg daily vol (3M) 1629

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
2.9B +1.4%
FY2026 Revenue FY2025–FY2026
Net Income
-33.12M -146.6%
FY2026 Net Income FY2025–FY2026
Operating Cash Flow
88.8M +188%
FY2026 Operating Cash Flow FY2025–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item TTM FY2026 FY2025
INR 2.94B 2.9B 2.86B
INR 7.38M 7.2M 6.55M
INR 6.31M 9.55M 6.74M
INR -16.04M -29.81M 98.86M
INR 6.04M 3.31M 27.74M
INR -22.07M -33.12M 71.12M
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2025–FY2026: 6.18M in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.